DIGITAL EDITION

ARCHIVES

Category: Past Articles

Worsening Choreoathetosis in Huntington’s Disease with Fluoxetine, Lisdexamfetamine, and Melatonin: A Case Report

By Clayton J. Hamilton, PharmD; Tysen K. Timmer, BA; Robert C. Munjal, MD; Fernando Cardozo-Pelaez, PhD; and Ian R. McGrane, PharmD Dr. Hamilton is with the Department of Pharmacy, Veteran’s

Atypical Neuroleptic Malignant Syndrome Precipitated By Clozapine And Quetiapine Overdose: A Diagnostic Challenge

By David Choon Liang Teo, MBBS, MRC Psych (UK), FAMS (Psychiatry); Hon Khuan Wong, MBBS; Sheng Neng Tan, MBBS, MMED (Psychiatry), FAMS (Psychiatry) Drs. Teo, Wong and Tan are with

Ethical Reflections On Offering Patients Accelerated Resolution Therapy (ART)

By Edmund G. Howe, MD, JD; Laney Rosenzweig, MS, LMRT; and Amy Shuman, MSW, LICSW, DCSW Dr. Howe is Professor of Psychiatry and Medicine, Uniformed Services University of the Health

Implementation of the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS™) Across Four Phase IIIB Clinical Trials in HIV-Infected Individuals (ARIA, STRIIVING, DAWNING and INSPIRING)

By Clare Brennan, DPT, MSPH; Hannah Whillis, MS; Choy Man, BS; Brian Wynne, MD; Vani Vannappagari, MBBS, MPH, PhD Dr. Brennan and and Ms. Man are with Clinical Development and

Risk Management: Licensing Board Complaints: What You Need To Know

By Ann McNary, JD Ms. McNary is Senior Risk Manager at PRMS, Inc. in Arlington, Virginia. Funding: No funding was provided for the preparation of this article. Disclosures: The authors

Letter to the Editor: Metabolic Changes in Patients with Schizophrenia Switched from Olanzapine to Asenaprine or Clozapine

By Masaru Nakamura, MD, PhD, and Takahiko Nagamine, MD, PhD Funding/financial disclosures: The author has no conflicts of interest relevant to the content of this letter. No funding was received

Letter to the Editor: Regarding Zika Microcephaly

By Beuy Joob, PhD, and Viroj Wiwanitkit, MD Funding/financial disclosures: The authors have no conflicts of interest relevant to the content of this letter. No funding was received for the

Letter to the Editor: Can YouTube® Disseminate Dementia Knowledge to Sinagpore Chinese?

By Benjamin K.P. Woo, MD Funding/financial disclosures: The authors have no conflicts of interest relevant to the content of this letter. No funding was received for the preparation of this

Editorial Message and Issue Highlights–Vol. 15, No. 5–6, May-June 2018

Dear Colleagues: Welcome to the May–June 2018 issue of Innovations in Clinical Neuroscience (ICNS). We start the issue with a timely review article by Touma and Scarff titled, “Valbenazine and

Atrial Fibrillation and Injected Aripiprazole: A Case Report

by Anthi Stefatos, MD; Julie N. Ha, PharmD; Adrian Baranchuk MD; Ross J. Baldessarini, MD; and Gustavo H. Vázquez MD, PhD Drs. Stefatos and Ha are with the Department of

Development of a Behavioral Health Stigma Measure and Application of Machine Learning for Classification

By Farah Tokmic, PhD; Mirsad Hadzikadic, PhD; James R. Cook, PhD; and Oleg V. Tcheremissine, MD Drs. Tokmic and Hadzikadic are with the Department of Software & Information Systems at

Delirium and Psychotic Symptoms Associated with Hyperglycemia in a Patient with Poorly controlled Type 2 Diabetes Mellitus

By Rui Lopes, MD, and Bernardo Dias Pereira, MD Dr. Lopes is with the Faculty of Medicine at the University of Porto in Porto, Portugal. Dr. Pereira is with the

Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Results from Two Randomized, Placebo-controlled Trials

by David V. Sheehan, MD, MBA; Maria Gasior, MD, PhD; Susan L. McElroy, MD; Jana Radewonuk, MSc; Barry K. Herman, MD, MMM; and James Hudson, MD, ScD Dr. Sheehan is

Combination Phentermine–Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study

By Anna I. Guerdjikova, PhD, LISW; Stephanie Williams, MS; Thomas J. Blom, MS; Nicole Mori, CNP; and Susan L. McElroy, MD Drs. Guerdjikova and McElroy and Ms. Mori are with

Valbenazine and Deutetrabenazine for Tardive Dyskinesia

By Katie T. B. Touma, PharmD, BCPP, BCPS, and Jonathan R. Scarff, MD Dr. Touma is with the William Jennings Bryan Dorn VA Medical Center Community-based Outpatient Clinic in Anderson,

Risk Management: Lessons to Be Learned: A Review of Post-suicide Malpractice Lawsuits

By Ann Mcnary, JD Ms. McNary is Senior Risk Manager at PRMS, Inc. in Arlington, Virginia. Funding: No funding was provided for the preparation of this article. Disclosures: Ms. McNary

Letter to the Editor: Kratom and the Opioid Crisis

Innov Clin Neurosci. 2018;15(5–6):11–12 Dr. Bestha is with the Carolinas Healthcare System in Charlotte, North Carolina. Funding/financial disclosures. The author has no conflicts of interest relevant to the content of

Editorial Message and Issue Highlights–Vol. 15, No. 3–4, March-April 2018

Dear Colleagues: Welcome to the March–April 2018 issue of Innovations in Clinical Neuroscience (ICNS). We are excited to lead this edition of ICNS with an exciting commentary by Dr. Michael